Don’t let endotoxins trick your conclusions: purified gelatin improves accuracy of 3D in vitro models
Recent changes in legislation and increased ethical considerations are driving a shift from pre-clinical animal trials to 3D models based on novel biomaterials. Using 3D bioprinting, it is possible to produce a pathophysiological environment that mimics human cells and tissues, creating optimal conditions to study the potential efficacy of new drugs.
Selecting the right biomaterial from the start of research is crucial to ensure successful 3D bioprinting and improve the accuracy of disease models. Alongside quality and consistency, one of the most crucial factors to consider is purity.
Recent breakthrough study shows low endotoxin levels improve reliability of 3D in vitro models
New research, led jointly by the University of Twente and Rousselot, has shown for the first time that the efficacy of 3D in vitro cancer models is significantly impacted by the presence of endotoxins.
In a first-of-its-kind study, the researchers investigated the impact of endotoxins on 3D breast cancer models, looking at both the effect on the crosstalk between macrophages and cancer cells and the effect on the measured efficacy of immunotherapies.
The study compared non-purified GelMA with naturally high endotoxin levels to Rousselot’s X-Pure® gelatin methacrylate (GelMA) – a purified biomaterial with low endotoxin levels.
The study found that endotoxin levels had a marked effect on the efficacy of the 3D-printed model in three aspects:
1. Inflammatory reaction: Materials with high levels of endotoxins produced a larger inflammatory reaction than those with lower endotoxin levels. In the biomaterial with high endotoxin levels, macrophages were 2.16 times larger and produced three times the amount of nitrous oxide, indicating a strong inflammatory response.
2. Receptivity of immune cells to cancer cells: Crosstalk between macrophages and cancer cells was significantly reduced in the presence of high endotoxin levels.
3. Reliability of therapeutic outcomes: The high endotoxin environment artificially increased the measured efficacy of the therapy designed to inhibit the expression of anti-inflammatory markers.
Crucially, the study demonstrates that high levels of endotoxins in biomaterials can lead to misinterpretation of the safety and potency of novel therapeutics, emphasizing the growing need for purified biomaterials.
The presence of endotoxins in biomaterials can negatively impact the credibility of 3D models.
Purified biomaterials can reduce the costs, time and ethical burden of drug development
Purified biomaterials help enhance the reliability and reproducibility of 3D printed models, creating new possibilities for replacing preclinical animal trials.
For drug developers looking to explore alternatives to animal testing, ultra-purified X-Pure GelMA is the ideal biomaterial to recreate in vivo conditions and leverage the power of 3D cell culture.
Beyond bioprinting: The expanding possibilities of gelatins and collagens in regenerative medicine
The possibilities of Rousselot’s X-Pure range extend far beyond bioprinting. As the field of biomaterials continues to progress rapidly due to ongoing advancements in chemistry, mechanobiology, cutting-edge technologies, novel cell sources, avant-garde drug delivery platforms, and bio fabrication processes, our experts are at the forefront of the latest scientific research to help our customers accelerate their biomedical innovations to market.
The unique advantages of gelatin as a biomaterial
Gelatin is a versatile and reliable biomaterial derived from native collagen, a natural protein found in the extracellular matrix of animals. Due to its unique properties – including cell recognition sites, excellent biocompatibility, low antigenicity and tunable biodegradability – gelatin provides a wide range of exciting opportunities in regenerative medicine. The simplicity of its molecular structure means it can be modified to improve its biological and functional properties, opening up a world of possibilities for biomaterials that can support innovations in tissue engineering, cellular therapy, advanced drug delivery and more.
Find the ideal (modified) gelatin solution to accelerate your next biomedical innovation
The mechanical properties of GelMA and gelatin can be customized to suit an ever-expanding list of biomedical applications. This can be as simple as varying the gel concentration, or as complex as coupling numerous types of natural, inorganic or organic polymers, natural proteins or polysaccharides to provide additional functionalized moieties. The benefits of gelatin‐composites can also be applied to other types of biomaterial platforms, such as 2D coatings.
At Rousselot, our team can help to tailor a custom gelatin solution to meet your specific requirements and guide you through regulations. With more than 130 years of gelatin expertise and strong leadership in this market, we are well positioned to collaborate with you to create custom biomaterial-based solutions for your pharmaceutical, medical device or ATMP.
Biomaterials that can take you from research to patient
Choosing premium gelatins will give your biomedical application the best chance of success. With high purity, batch-to-batch consistency, customizability and functional equivalence between research grade and GMP grade biomaterials, Rousselot’s high-quality X-Pure range can be used throughout the entire clinical translation pathway, from research to patient.
To find out more about the exceptional possibilities of X-Pure – visit our expert team at Booth 572.
Read our latest paper: Heinrich, M. A., Heinrich, L., Ankone, M. J. K., Vergauwen, B., & Prakash, J. (2023). Endotoxin contamination alters macrophage-cancer cell interaction and therapeutic efficacy in pre-clinical 3D in vitro models. Biomaterials advances, 144, 213220. https://doi.org/10.1016/j.bioadv.2022.213220
Recent changes in legislation and increased ethical considerations are driving a shift from pre-clinical animal trials to 3D models based on novel biomaterials. Using 3D bioprinting, it is possible to produce a pathophysiological environment that mimics human cells and tissues, creating optimal conditions to study the potential efficacy of new drugs.
Selecting the right biomaterial from the start of research is crucial to ensure successful 3D bioprinting and improve the accuracy of disease models. Alongside quality and consistency, one of the most crucial factors to consider is purity.
Recent breakthrough study shows low endotoxin levels improve reliability of 3D in vitro models
New research, led jointly by the University of Twente and Rousselot, has shown for the first time that the efficacy of 3D in vitro cancer models is significantly impacted by the presence of endotoxins.
In a first-of-its-kind study, the researchers investigated the impact of endotoxins on 3D breast cancer models, looking at both the effect on the crosstalk between macrophages and cancer cells and the effect on the measured efficacy of immunotherapies.
The study compared non-purified GelMA with naturally high endotoxin levels to Rousselot’s X-Pure® gelatin methacrylate (GelMA) – a purified biomaterial with low endotoxin levels.
The study found that endotoxin levels had a marked effect on the efficacy of the 3D-printed model in three aspects:
1. Inflammatory reaction: Materials with high levels of endotoxins produced a larger inflammatory reaction than those with lower endotoxin levels. In the biomaterial with high endotoxin levels, macrophages were 2.16 times larger and produced three times the amount of nitrous oxide, indicating a strong inflammatory response.
2. Receptivity of immune cells to cancer cells: Crosstalk between macrophages and cancer cells was significantly reduced in the presence of high endotoxin levels.
3. Reliability of therapeutic outcomes: The high endotoxin environment artificially increased the measured efficacy of the therapy designed to inhibit the expression of anti-inflammatory markers.
Crucially, the study demonstrates that high levels of endotoxins in biomaterials can lead to misinterpretation of the safety and potency of novel therapeutics, emphasizing the growing need for purified biomaterials.
The presence of endotoxins in biomaterials can negatively impact the credibility of 3D models.
Purified biomaterials can reduce the costs, time and ethical burden of drug development
Purified biomaterials help enhance the reliability and reproducibility of 3D printed models, creating new possibilities for replacing preclinical animal trials.
For drug developers looking to explore alternatives to animal testing, ultra-purified X-Pure GelMA is the ideal biomaterial to recreate in vivo conditions and leverage the power of 3D cell culture.
Beyond bioprinting: The expanding possibilities of gelatins and collagens in regenerative medicine
The possibilities of Rousselot’s X-Pure range extend far beyond bioprinting. As the field of biomaterials continues to progress rapidly due to ongoing advancements in chemistry, mechanobiology, cutting-edge technologies, novel cell sources, avant-garde drug delivery platforms, and bio fabrication processes, our experts are at the forefront of the latest scientific research to help our customers accelerate their biomedical innovations to market.
The unique advantages of gelatin as a biomaterial
Gelatin is a versatile and reliable biomaterial derived from native collagen, a natural protein found in the extracellular matrix of animals. Due to its unique properties – including cell recognition sites, excellent biocompatibility, low antigenicity and tunable biodegradability – gelatin provides a wide range of exciting opportunities in regenerative medicine. The simplicity of its molecular structure means it can be modified to improve its biological and functional properties, opening up a world of possibilities for biomaterials that can support innovations in tissue engineering, cellular therapy, advanced drug delivery and more.
Find the ideal (modified) gelatin solution to accelerate your next biomedical innovation
The mechanical properties of GelMA and gelatin can be customized to suit an ever-expanding list of biomedical applications. This can be as simple as varying the gel concentration, or as complex as coupling numerous types of natural, inorganic or organic polymers, natural proteins or polysaccharides to provide additional functionalized moieties. The benefits of gelatin‐composites can also be applied to other types of biomaterial platforms, such as 2D coatings.
At Rousselot, our team can help to tailor a custom gelatin solution to meet your specific requirements and guide you through regulations. With more than 130 years of gelatin expertise and strong leadership in this market, we are well positioned to collaborate with you to create custom biomaterial-based solutions for your pharmaceutical, medical device or ATMP.
Biomaterials that can take you from research to patient
Choosing premium gelatins will give your biomedical application the best chance of success. With high purity, batch-to-batch consistency, customizability and functional equivalence between research grade and GMP grade biomaterials, Rousselot’s high-quality X-Pure range can be used throughout the entire clinical translation pathway, from research to patient.
To find out more about the exceptional possibilities of X-Pure – visit our expert team at Booth 572.
Read our latest paper: Heinrich, M. A., Heinrich, L., Ankone, M. J. K., Vergauwen, B., & Prakash, J. (2023). Endotoxin contamination alters macrophage-cancer cell interaction and therapeutic efficacy in pre-clinical 3D in vitro models. Biomaterials advances, 144, 213220. https://doi.org/10.1016/j.bioadv.2022.213220
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
